文献速递呼吸道感染呼吸危重症与机械通气

脓毒症分子表型的识别:两项前瞻性队列分析及两项随机对照试验的二次分析

Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials.
PubMed 文献 · Lancet Respir Med · 2023-08-23

研究利用VALID(N=1140)和EARLI(N=818)两个前瞻性脓毒症队列的血浆生物标志物与临床数据进行潜伏类别分析,独立识别出低炎症型与高炎症型两个分子表型。高炎症型患者炎症细胞因子更高、升压药使用更多、菌血症更多、蛋白C更低且死亡率更高;该表型与既往ARDS表型高度一致,并在PROWESS-SHOCK试验中对活化蛋白C的治疗反应存在表型差异。

要点

  • 脓毒症可稳定分为低炎症型与高炎症型两个分子表型
  • 高炎症型病情更重、死亡率更高,且与ARDS表型高度一致
  • PROWESS-SHOCK中活化蛋白C疗效随表型不同而异(p=0·0043)

核心结论

  • 既往在ARDS中识别的分子表型同样可在多个脓毒症队列中识别,且对活化蛋白C的治疗反应不同
  • 分子表型可能成为超越综合征诊断的可治疗特征

研究设计与样本

  • 基于两个前瞻性观察队列VALID(N=1140)与EARLI(N=818)的临床数据和血浆生物标志物进行潜伏类别分析
  • 对PROWESS-SHOCK与VASST两项随机对照试验进行回顾性二次分析以评估治疗效果异质性

主要发现

  • 两类别模型对VALID和EARLI拟合最佳(p<0·0001)
  • VALID中804例(70·5%)为低炎症型、336例(29·5%)为高炎症型;EARLI中530例(64·8%)为低炎症型、288例(35·2%)为高炎症型
  • 高炎症型较低炎症型血浆促炎细胞因子更高、升压药使用更多、菌血症更多、蛋白C更低、死亡率更高(p<0·0001)
  • 分类模型显示脓毒症表型与既往ARDS表型高度一致(AUC 0·87–0·96,随模型而异)
  • PROWESS-SHOCK中1142例(68·0%)为低炎症型、538例(32·0%)为高炎症型,对活化蛋白C的反应因表型而异(p=0·0043);VASST中未观察到与升压药类型的治疗交互作用(p=0·72)

关键数值与推荐

  • VALID两类别模型:低炎症型70·5%、高炎症型29·5%
  • EARLI两类别模型:低炎症型64·8%、高炎症型35·2%
  • 脓毒症与ARDS表型一致性AUC 0·87–0·96
  • PROWESS-SHOCK中活化蛋白C治疗反应的表型交互作用p=0·0043
  • VASST中升压药类型治疗交互作用p=0·72

临床怎么用

  • 对脓毒症患者可考虑基于血浆生物标志物进行分子表型分型以指导治疗选择
  • 高炎症型患者病情更重,需更密切关注血流动力学与感染控制
  • 表型分型有望用于富集人群的临床试验设计与精准治疗

局限性

  • 两个随机对照试验的分析为回顾性二次分析
  • 研究基于既有队列与试验数据,分子表型的临床可操作性尚需前瞻性验证

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In sepsis and acute respiratory distress syndrome (ARDS), heterogeneity has contributed to difficulty identifying effective pharmacotherapies. In ARDS, two molecular phenotypes (hypoinflammatory and hyperinflammatory) have consistently been identified, with divergent outcomes and treatment responses. In this study, we sought to derive molecular phenotypes in critically ill adults with sepsis, determine their overlap with previous ARDS phenotypes, and evaluate whether they respond differently to treatment in completed sepsis trials. METHODS: We used clinical data and plasma biomarkers from two prospective sepsis cohorts, the Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study (N=1140) and the Early Assessment of Renal and Lung Injury (EARLI) study (N=818), in latent class analysis (LCA) to identify the optimal number of classes in each cohort independently. We used validated models trained to classify ARDS phenotypes to evaluate concordance of sepsis and ARDS phenotypes. We applied these models retrospectively to the previously published Prospective Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis and Septic Shock (PROWESS-SHOCK) trial and Vasopressin and Septic Shock Trial (VASST) to assign phenotypes and evaluate heterogeneity of treatment effect. FINDINGS: A two-class model best fit both VALID and EARLI (p<0·0001). In VALID, 804 (70·5%) of the 1140 patients were classified as hypoinflammatory and 336 (29·5%) as hyperinflammatory; in EARLI, 530 (64·8%) of 818 were hypoinflammatory and 288 (35·2%) hyperinflammatory. We observed higher plasma pro-inflammatory cytokines, more vasopressor use, more bacteraemia, lower protein C, and higher mortality in the hyperinflammatory than in the hypoinflammatory phenotype (p<0·0001 for all). Classifier models indicated strong concordance between sepsis phenotypes and previously identified ARDS phenotypes (area under the curve 0·87-0·96, depending on the model). Findings were similar excluding participants with both sepsis and ARDS. In PROWESS-SHOCK, 1142 (68·0%) of 1680 patients had the hypoinflammatory phenotype and 538 (32·0%) had the hyperinflammatory phenotype, and response to activated protein C differed by phenotype (p=0·0043). In VASST, phenotype proportions were similar to other cohorts; however, no treatment interaction with the type of vasopressor was observed (p=0·72). INTERPRETATION: Molecular phenotypes previously identified in ARDS are also identifiable in multiple sepsis cohorts and respond differently to activated protein C. Molecular phenotypes could represent a treatable trait in critical illness beyond the patient's syndromic diagnosis. FUNDING: US National Institutes of Health.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Sinha P, Kerchberger VE, Willmore A, et al. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. Lancet Respir Med. 2023. PMID: 37633303. doi:10.1016/S2213-2600(23)00237-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。